6月6日，ImmunityBio盘中下跌5.01%，报6.925美元/股，成交额5331.82万美元。该股自5月下旬以来持续承压，延续多重利好兑现后的获利了结态势。
消息面上，此前ImmunityBio密集释放催化剂，包括AUA临床疗效数据、ISPOR卫生经济学分析显示ANKTIVA联合BCG较TAR-200更具成本效益，以及竞争对手enGene关键临床数据失败带来的竞争格局利好。尽管5月26日曾借数据反弹，但未能扭转趋势，股价自5月21日高点持续走低，本次下探至6.925美元为近期新低，显示市场对前期利好的消化仍在延续。
ImmunityBio是一家晚期免疫治疗公司，专注激活先天和适应性免疫系统治疗肿瘤及传染病，拥有自然杀伤细胞疗法、抗体细胞因子融合蛋白及疫苗载体综合平台。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.